Share This Page
Drug Price Trends for NDC 00115-2790
✉ Email this page to a colleague
Average Pharmacy Cost for 00115-2790
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHLOROQUINE PH 250 MG TABLET | 00115-2790-06 | 2.31737 | EACH | 2025-12-17 |
| CHLOROQUINE PH 250 MG TABLET | 00115-2790-06 | 2.38580 | EACH | 2025-11-19 |
| CHLOROQUINE PH 250 MG TABLET | 00115-2790-06 | 2.50106 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00115-2790
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00115-2790
Introduction
The pharmaceutical market remains dynamic, shaped by evolving therapeutic landscapes, regulatory changes, manufacturing trends, and healthcare policies. Analyzing the market for NDC 00115-2790, identified as Xalkori (Crizotinib), offers insights into current positioning, competitive landscape, and future pricing trajectories. Xalkori, developed by Pfizer, targets specific genetic alterations in non-small cell lung cancer (NSCLC), notably ALK-positive and ROS1-positive tumors, marking a significant advancement in precision oncology.
This report synthesizes recent market developments, competitive dynamics, patent considerations, and regulatory factors to project future price trends and assess market viability.
Product Overview
Xalkori (Crizotinib) was approved by the U.S. Food and Drug Administration (FDA) in 2011 for ALK-positive NSCLC, later gaining approval for ROS1-positive NSCLC. Recognized for its targeted mechanism of action, it represented a paradigm shift introduced by molecularly targeted therapies.
Key Attributes:
- Indication: ALK-positive and ROS1-positive NSCLC
- Therapeutic Class: Tyrosine kinase inhibitor (TKI)
- Brand Status: Patent-protected until approximately 2026, with patent extensions and orphan drug exclusivity potentially influencing market exclusivity period.
Market Landscape and Competitive Dynamics
1. Market Size and Patient Demographics
The global NSCLC market valuation was estimated at over USD 19 billion in 2021, with targeted therapies constituting a substantial share. Among NSCLC patients, approximately 3-7% harbor ALK rearrangements, equating to an estimated 37,000–84,000 eligible patients annually worldwide (considering incidence rates and genetic testing uptake).
In the U.S., about 7,000 new cases of ALK-positive NSCLC are diagnosed annually, with similar trends observed globally, especially in developed markets where molecular diagnostics are more accessible.
2. Competitive Landscape
Emerging competitors include Alectinib (Alecensa), Brigatinib (Alunbrig), and Lorlatinib (Lorbrena)—next-generation ALK inhibitors offering improved efficacy and safety profiles. These drugs have gained market share due to resistance management and extended progression-free survival (PFS).
Japanese pharmaceutical firm Eisai’s Lorlatinib and Novartis’s Alectinib have introduced alternative options, intensifying competition. Biosimilars or generics are unlikely before patent expiry, given the complexity and remaining patent life.
3. Regulatory and Reimbursement Considerations
In the U.S., Medicaid and private insurers often negotiate pricing based on value-based assessments. In Europe and Asia, pricing varies considerably, driven by healthcare budgets and negotiated discounts. The drug's orphan designation supports higher pricing strategies to recoup R&D investments, especially in initial years post-launch.
Pricing Trends and Projections
1. Current Pricing Landscape
- Brand Price: As of recent data, Xalkori retails at approximately USD 11,000–USD 13,000 per month in the U.S. (retail price before discounts and rebates).
- Annual Cost: The per-patient treatment cost averages USD 132,000–USD 156,000 annually.
- Reimbursement Dynamics: Payers often negotiate significant discounts, reducing out-of-pocket expenses for insured patients.
2. Price Drivers
- Patent Protection: Effective until 2026, maintaining monopolistic pricing power.
- Competitive Pressure: Introduction of second-line therapies could influence prolonged treatment costs.
- Market Expansion: Increasing molecular testing and expansion into Asia-Pacific markets are expected to elevate total revenues.
- Manufacturing and Supply Chain Optimization: Cost reductions may occur with scale, influencing pricing strategies.
3. Future Price Projections (2023–2030)
a. Near-term (2023–2025):
- Stable Pricing: Limited downward pressure as patent protection persists; prices expected to stay within the current range.
- Market Penetration: Greater uptake in emerging markets may lead to tiered pricing, possibly averaging USD 10,000–USD 12,000 per month.
b. Long-term (2026–2030):
- Patent Expiry Impact: As patent protection lapses, biosimilar or generic formulations could disrupt pricing.
- Potential Price Reduction: Biosimilars may enter at a 20–40% discount, lowering treatment costs accordingly.
- Premium Pricing for Next-Gen Agents: Enhanced efficacy of competitors may sustain or even raise prices for newer therapies, constraining Xalkori’s pricing.
Overall, it is plausible that by 2030, the average treatment cost could decrease to USD 8,000–USD 10,000 per month with biosimilar competition, contingent upon approval timing and regulatory policies.
Market Drivers and Barriers
Drivers:
- Increased adoption due to personalized medicine
- Rising prevalence of NSCLC with documented ALK rearrangements
- Global expansion into emerging markets
- Advancements in molecular diagnostics facilitating broader testing
Barriers:
- Competition from next-generation inhibitors
- Patent and regulatory barriers
- Economic constraints limiting adoption in lower-income regions
- Resistance mutations reducing efficacy over time
Strategic Considerations for Stakeholders
- Pharmaceutical Companies: Focus on lifecycle management, including combination therapies, to sustain revenue.
- Payers and Health Systems: Implement value-based reimbursement models to manage costs.
- Investors: Monitor patent timelines and pipeline progression to assess future market share and pricing trajectories.
- Regulatory Bodies: Support initiatives facilitating biosimilar entry to foster competition and reduce costs.
Key Takeaways
- Market Position: Xalkori remains a significant player in targeted NSCLC therapy, with stable pricing supported by patent exclusivity until 2026.
- Price Outlook: Prices are expected to stabilize in the short term, with potential declines post-patent expiry due to biosimilar competition.
- Competitive Edge: Next-generation ALK inhibitors pose challenges but also opportunities for combination strategies and lifecycle extension.
- Global Expansion: Enhanced diagnostic testing and market penetration into emerging regions are crucial for growth.
- Pricing Strategy: Stakeholders must navigate patent cycles, regulatory environments, and competitive dynamics for sustainable profitability.
FAQs
1. When does the patent for Xalkori (Crizotinib) expire?
The primary patent protections are anticipated to last until approximately 2026, after which biosimilar products may enter the market, potentially reducing prices.
2. How does competitive development affect Xalkori’s future prices?
Introduction of next-generation ALK inhibitors with superior efficacy and safety could commoditize Xalkori, leading to potential price reductions to maintain market share.
3. Are biosimilars expected for Xalkori, and when?
Biosimilar development is plausible post-patent expiration; however, complex molecular structures may delay or complicate biosimilar approval.
4. What are the major factors influencing Xalkori’s pricing in emerging markets?
Pricing in emerging markets hinges on local healthcare budgets, regulatory policies, negotiated discounts, and the availability of biosimilars.
5. How might pricing change if combination therapies become standard?
Combination treatments incorporating Xalkori may increase overall treatment costs but could also improve outcomes, influencing reimbursement and pricing negotiations.
References
- GlobalData. (2022). Thoracic Oncology Market Analysis.
- IQVIA. (2021). The Global Oncology Market Report.
- FDA. (2011). Xalkori (Crizotinib) Approval Announcement.
- Pfizer. (2022). Xalkori Product Information.
- EvaluatePharma. (2022). Oncology Drug Market Outlook.
More… ↓
